NASDAQ:SELB

Selecta Biosciences Competitors

$3.90
-0.08 (-2.01 %)
(As of 04/15/2021 12:32 PM ET)
Add
Compare
Today's Range
$3.86
Now: $3.90
$3.99
50-Day Range
$3.70
MA: $4.23
$4.68
52-Week Range
$1.47
Now: $3.90
$5.70
Volume14,963 shs
Average Volume1.76 million shs
Market Capitalization$438.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18

Competitors

Selecta Biosciences (NASDAQ:SELB) Vs. PAND, FPRX, FGEN, AMRX, CYTK, and PRLD

Should you be buying SELB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Selecta Biosciences, including Pandion Therapeutics (PAND), Five Prime Therapeutics (FPRX), FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), Cytokinetics (CYTK), and Prelude Therapeutics (PRLD).

Selecta Biosciences (NASDAQ:SELB) and Pandion Therapeutics (NASDAQ:PAND) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

56.9% of Selecta Biosciences shares are held by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are held by institutional investors. 22.4% of Selecta Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Selecta Biosciences and Pandion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Selecta BiosciencesN/AN/A-54.69%
Pandion TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Selecta Biosciences and Pandion Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Selecta Biosciences01602.86
Pandion Therapeutics02202.50

Selecta Biosciences presently has a consensus target price of $7.20, suggesting a potential upside of 86.05%. Pandion Therapeutics has a consensus target price of $44.25, suggesting a potential downside of 26.31%. Given Selecta Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Selecta Biosciences is more favorable than Pandion Therapeutics.

Earnings and Valuation

This table compares Selecta Biosciences and Pandion Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Selecta Biosciences$6.68 million65.10$-55,350,000.00($1.22)-3.17
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A

Pandion Therapeutics has lower revenue, but higher earnings than Selecta Biosciences.

Summary

Selecta Biosciences beats Pandion Therapeutics on 6 of the 9 factors compared between the two stocks.

Selecta Biosciences (NASDAQ:SELB) and Five Prime Therapeutics (NASDAQ:FPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Risk & Volatility

Selecta Biosciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500.

Institutional & Insider Ownership

56.9% of Selecta Biosciences shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 22.4% of Selecta Biosciences shares are held by company insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Selecta Biosciences and Five Prime Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Selecta BiosciencesN/AN/A-54.69%
Five Prime Therapeutics-554.71%-75.84%-49.08%

Analyst Ratings

This is a summary of current recommendations and price targets for Selecta Biosciences and Five Prime Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Selecta Biosciences01602.86
Five Prime Therapeutics06202.25

Selecta Biosciences presently has a consensus target price of $7.20, suggesting a potential upside of 86.05%. Five Prime Therapeutics has a consensus target price of $30.7143, suggesting a potential downside of 19.15%. Given Selecta Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Selecta Biosciences is more favorable than Five Prime Therapeutics.

Earnings and Valuation

This table compares Selecta Biosciences and Five Prime Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Selecta Biosciences$6.68 million65.10$-55,350,000.00($1.22)-3.17
Five Prime Therapeutics$14.87 million118.98$-137,200,000.00($3.92)-9.69

Selecta Biosciences has higher earnings, but lower revenue than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Selecta Biosciences beats Five Prime Therapeutics on 9 of the 14 factors compared between the two stocks.

Selecta Biosciences (NASDAQ:SELB) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Volatility & Risk

Selecta Biosciences has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Insider and Institutional Ownership

56.9% of Selecta Biosciences shares are owned by institutional investors. Comparatively, 75.1% of FibroGen shares are owned by institutional investors. 22.4% of Selecta Biosciences shares are owned by company insiders. Comparatively, 3.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Selecta Biosciences and FibroGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Selecta BiosciencesN/AN/A-54.69%
FibroGen-191.78%-48.19%-27.72%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Selecta Biosciences and FibroGen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Selecta Biosciences01602.86
FibroGen15202.13

Selecta Biosciences currently has a consensus target price of $7.20, suggesting a potential upside of 86.05%. FibroGen has a consensus target price of $45.8333, suggesting a potential upside of 134.56%. Given FibroGen's higher possible upside, analysts clearly believe FibroGen is more favorable than Selecta Biosciences.

Earnings & Valuation

This table compares Selecta Biosciences and FibroGen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Selecta Biosciences$6.68 million65.10$-55,350,000.00($1.22)-3.17
FibroGen$256.58 million6.97$-76,970,000.00($0.89)-21.96

Selecta Biosciences has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Selecta Biosciences beats FibroGen on 8 of the 14 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and Selecta Biosciences (NASDAQ:SELB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.9% of Selecta Biosciences shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 22.4% of Selecta Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Amneal Pharmaceuticals and Selecta Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amneal Pharmaceuticals$1.63 billion1.08$-361,920,000.00$0.2721.74
Selecta Biosciences$6.68 million65.10$-55,350,000.00($1.22)-3.17

Selecta Biosciences has lower revenue, but higher earnings than Amneal Pharmaceuticals. Selecta Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Amneal Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Selecta Biosciences has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Profitability

This table compares Amneal Pharmaceuticals and Selecta Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amneal Pharmaceuticals3.30%42.02%3.82%
Selecta BiosciencesN/AN/A-54.69%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Amneal Pharmaceuticals and Selecta Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amneal Pharmaceuticals02502.71
Selecta Biosciences01602.86

Amneal Pharmaceuticals currently has a consensus price target of $6.5714, indicating a potential upside of 11.95%. Selecta Biosciences has a consensus price target of $7.20, indicating a potential upside of 86.05%. Given Selecta Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Selecta Biosciences is more favorable than Amneal Pharmaceuticals.

Summary

Amneal Pharmaceuticals beats Selecta Biosciences on 8 of the 14 factors compared between the two stocks.

Selecta Biosciences (NASDAQ:SELB) and Cytokinetics (NASDAQ:CYTK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Selecta Biosciences and Cytokinetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Selecta Biosciences01602.86
Cytokinetics011002.91

Selecta Biosciences presently has a consensus target price of $7.20, indicating a potential upside of 86.05%. Cytokinetics has a consensus target price of $33.6364, indicating a potential upside of 32.58%. Given Selecta Biosciences' higher probable upside, equities analysts clearly believe Selecta Biosciences is more favorable than Cytokinetics.

Volatility & Risk

Selecta Biosciences has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.

Institutional and Insider Ownership

56.9% of Selecta Biosciences shares are held by institutional investors. Comparatively, 97.1% of Cytokinetics shares are held by institutional investors. 22.4% of Selecta Biosciences shares are held by insiders. Comparatively, 6.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Selecta Biosciences and Cytokinetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Selecta Biosciences$6.68 million65.10$-55,350,000.00($1.22)-3.17
Cytokinetics$26.87 million67.54$-121,690,000.00($2.11)-12.02

Selecta Biosciences has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Selecta Biosciences and Cytokinetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Selecta BiosciencesN/AN/A-54.69%
Cytokinetics-209.88%-3,065.14%-36.39%

Prelude Therapeutics (NASDAQ:PRLD) and Selecta Biosciences (NASDAQ:SELB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Institutional and Insider Ownership

76.2% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 56.9% of Selecta Biosciences shares are held by institutional investors. 22.4% of Selecta Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Prelude Therapeutics and Selecta Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude TherapeuticsN/AN/AN/AN/AN/A
Selecta Biosciences$6.68 million65.10$-55,350,000.00($1.22)-3.17

Prelude Therapeutics has higher earnings, but lower revenue than Selecta Biosciences.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Prelude Therapeutics and Selecta Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prelude Therapeutics03102.25
Selecta Biosciences01602.86

Prelude Therapeutics currently has a consensus target price of $54.25, indicating a potential upside of 51.07%. Selecta Biosciences has a consensus target price of $7.20, indicating a potential upside of 86.05%. Given Selecta Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Selecta Biosciences is more favorable than Prelude Therapeutics.

Profitability

This table compares Prelude Therapeutics and Selecta Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prelude TherapeuticsN/AN/AN/A
Selecta BiosciencesN/AN/A-54.69%

Summary

Selecta Biosciences beats Prelude Therapeutics on 5 of the 7 factors compared between the two stocks.

Ad Street Signals
Medtech Stock With Upside
Breakthrough imaging tech could quickly transform breast cancer surgery

Selecta Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.99-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
FibroGen logo
FGEN
FibroGen
1.8$19.54-1.4%$1.76 billion$256.58 million-7.49Analyst Report
Gap Down
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.87-0.9%$1.74 billion$1.63 billion14.32Analyst Report
Decrease in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.37-4.4%$1.74 billion$26.87 million-13.28Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.91-3.2%$1.73 billionN/A0.00Analyst Upgrade
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.86-2.1%$1.71 billion$428.41 million15.74
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.5$32.06-0.6%$1.69 billion$392.76 million13.30Analyst Upgrade
Analyst Revision
News Coverage
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$24.00-1.4%$1.68 billion$2.34 million-10.17
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.71-1.3%$1.65 billionN/A0.00Analyst Revision
Gap Up
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.69-0.8%$1.60 billion$320,000.00-8.63News Coverage
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.66-0.7%$1.59 billionN/A-6.28Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.33-0.3%$1.58 billion$145.97 million-7.02
uniQure logo
QURE
uniQure
1.7$35.39-1.4%$1.57 billion$7.28 million-9.39
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.72-1.2%$1.54 billion$175.34 million-15.13Analyst Report
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.74-1.6%$1.52 billion$82.27 million-18.88
Generation Bio logo
GBIO
Generation Bio
1.8$27.49-3.3%$1.50 billionN/A0.00Insider Selling
Increase in Short Interest
News Coverage
Gap Down
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$34.06-3.1%$1.48 billionN/A0.00Insider Selling
Increase in Short Interest
Gap Up
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.00-2.2%$1.48 billionN/A0.00
Endo International logo
ENDP
Endo International
1.3$6.22-0.8%$1.45 billion$2.91 billion-9.15
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.74-4.0%$1.44 billion$4.23 million-19.81Increase in Short Interest
OLMA
Olema Pharmaceuticals
1.6$35.09-2.2%$1.44 billionN/A0.00Increase in Short Interest
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$63.07-2.5%$1.43 billionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$35.68-0.0%$1.42 billionN/A-148.67
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.90-1.3%$1.42 billion$19.89 million-13.63Analyst Report
Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$28.20-0.4%$1.41 billionN/A-3.06Gap Down
ATBPD
Antibe Therapeutics
0.1$3.62-1.1%$1.40 billion$7.51 million-6.03
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.43-0.6%$1.39 billion$73.41 million-4.53Unusual Options Activity
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-2.4%$1.39 billion$6.20 million-14.39Gap Down
Zymeworks logo
ZYME
Zymeworks
1.8$30.24-0.7%$1.39 billion$29.54 million-8.02
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.00-10.6%$1.39 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$36.07-0.3%$1.32 billionN/A0.00Analyst Upgrade
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$34.68-1.3%$1.27 billionN/A0.00
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$33.56-2.2%$1.26 billionN/A-18.64
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.55-0.3%$1.26 billion$4.23 million-9.25Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$21.88-0.6%$1.23 billionN/A0.00Insider Selling
Unusual Options Activity
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$39.16-2.1%$1.20 billionN/A-2.80Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.98-1.9%$1.19 billion$261.02 million6.11
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$17.40-1.5%$1.18 billion$42.12 million-12.89Unusual Options Activity
News Coverage
NKTX
Nkarta
1.8$37.32-3.6%$1.18 billionN/A0.00Increase in Short Interest
Gap Down
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$20.00-3.9%$1.17 billion$59.70 million-200.00
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$27.44-2.4%$1.17 billionN/A-9.24Insider Selling
Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.67-5.0%$1.15 billion$35.22 million-7.79
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.61-2.3%$1.14 billion$230,000.00-12.38
MannKind logo
MNKD
MannKind
1.4$4.47-2.0%$1.14 billion$63.04 million-21.28Increase in Short Interest
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.84-3.6%$1.11 billionN/A-7.11
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$23.57-2.1%$1.10 billionN/A-8.70
Omeros logo
OMER
Omeros
1.4$17.68-0.7%$1.09 billion$111.81 million-7.43
Zogenix logo
ZGNX
Zogenix
1.7$19.51-0.4%$1.08 billion$3.65 million-2.05
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.53-1.0%$1.08 billion$57.05 million0.00
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.